Cryo-Cell Posts Higher Q3 Profit on Flat Revenue
Cryo-Cell International reported fiscal third-quarter 2026 revenue of $7.82 million, essentially unchanged from $7.83 million a year earlier. Net income rose to $1.27 million, or $0.16 per share, from $749,000, or $0.09 per share. The company operates private and public cord blood banks and stores more than 250,000 specimens.
Cryo-Cell’s quarter closed August 31, 2026. Sales were nearly level year over year at $7.82 million, while profit climbed to $1.27 million, or $0.16 per share, from $749,000, or $0.09 per share.
The company traces its start to 1989 and says it pioneered private cord blood banking, beginning stem cell separation and storage in 1992. It keeps more than 250,000 cord blood and tissue samples. Its Duke University-linked public program has supported over 900 transplants, and its facility holds FDA registration, cGMP/cGTP compliance, AABB accreditation, and FACT accreditation.
The results may matter most to expectant families and transplant patients who rely on cord blood repositories. A more profitable quarter could help Cryo-Cell maintain storage operations, public donations, and research partnerships, though flat revenue may limit expansion. Society could benefit if stable finances support broader availability of cord blood units for treatment and regenerative medicine, but actual effects depend on future investment and clinical demand.